Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

96.31 +1.89 (+2.01%)
Streaming Delayed Price Updated: 1:51 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,082,375
Open 95.42
Bid (Size) 96.10 (100)
Ask (Size) 96.53 (600)
Prev. Close 94.42
Today's Range 94.56 - 98.69
52wk Range 34.88 - 120.74
Shares Outstanding 101,298,669
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know
A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court... 
Via StockStory
Topics Economy Government World Trade
Guardant Health Inc (NASDAQ:GH) Posts Strong Q4 Revenue Beat and Bullish 2026 Outlook ↗
Via Chartmill

Performance

YTD
-5.3%
-5.3%
1 Month
-16.1%
-16.1%
3 Month
-13.4%
-13.4%
6 Month
+55.6%
+55.6%
1 Year
+126.9%
+126.9%

More News

Read More
News headline image
Guardant Health (NASDAQ:GH) Surprises With Q4 CY2025 Sales
Via StockStory
News headline image
Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
From Guardant Health, Inc.
Via Business Wire
News headline image
Earnings To Watch: Guardant Health (GH) Reports Q4 Results Tomorrow
Via StockStory
Topics Artificial Intelligence Economy World Trade
News headline image
3 Unprofitable Stocks Walking a Fine Line
Via StockStory
News headline image
Small Caps Roar: Russell 2000 Surges as Cooling Inflation Ignites Rate Cut Hopes
Via MarketMinute
Topics Bonds ETFs Economy
News headline image
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
News headline image
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions
From Guardant Health, Inc.
Via Business Wire
News headline image
3 Unpopular Stocks We Think Twice About
Via StockStory
News headline image
Should You Buy Guardant Health Before Feb. 19? ↗
Via The Motley Fool
Topics Earnings
News headline image
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health (NASDAQ:GH): Strongest Q3 Results from the Testing & Diagnostics Services Group
Via StockStory
News headline image
CS Diagnostics (OTCQB: CSDX) Advances Infection Control and Oncology Innovation Plus – IVP, SAFX, JTAI, OCG, BMXI Inside
Via AB Newswire
Topics Intellectual Property
News headline image
GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth
Via MarketMinute
News headline image
Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization
Via MarketMinute
News headline image
Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability
Via MarketMinute
Topics Artificial Intelligence Death
News headline image
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families
From Guardant Health, Inc.
Via Business Wire
News headline image
BTIG's Top Stock Picks for H1 2026: Navigating the New 'Application' Era
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
1 Growth Stock Set to Flourishand 2 We Avoid
Via StockStory
News headline image
The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Guardant Health, Inc.
Via Business Wire

Frequently Asked Questions

Is Guardant Health, Inc. - Common Stock publicly traded?
Yes, Guardant Health, Inc. - Common Stock is publicly traded.
What exchange does Guardant Health, Inc. - Common Stock trade on?
Guardant Health, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Guardant Health, Inc. - Common Stock?
The ticker symbol for Guardant Health, Inc. - Common Stock is GH on the Nasdaq Stock Market
What is the current price of Guardant Health, Inc. - Common Stock?
The current price of Guardant Health, Inc. - Common Stock is 96.31
When was Guardant Health, Inc. - Common Stock last traded?
The last trade of Guardant Health, Inc. - Common Stock was at 02/24/26 01:51 PM ET
What is the market capitalization of Guardant Health, Inc. - Common Stock?
The market capitalization of Guardant Health, Inc. - Common Stock is 9.76B
How many shares of Guardant Health, Inc. - Common Stock are outstanding?
Guardant Health, Inc. - Common Stock has 10B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.